Adam Cutler is the chief financial officer at Mural Oncology.
Prior to joining Mural, Mr. Cutler served as the chief financial officer at Q32 Bio Inc., a privately held biotechnology company. Prior to joining Q32, Mr. Cutler was chief financial officer at Molecular Templates, Inc., a publicly traded biopharmaceutical company. Mr. Cutler served as senior vice president, corporate affairs at Arbutus Biopharma Corporation, a publicly traded biopharmaceutical company. He was a managing director for The Trout Group LLC and Trout Capital LLC, where he executed financings and advised public and private life science companies on investor relations and capital raising strategies.
Mr. Cutler was a biotechnology equity research analyst at Bank of America Securities, JMP Securities, Canaccord Genuity, and Credit Suisse. Mr. Cutler previously served on the board of directors for InMed Pharmaceuticals Inc., a public pharmaceutical company, and Navidea Biopharmaceuticals, Inc. a public biopharmaceutical company.
Mr. Cutler holds a B.A. degree in economics from Brandeis University.